Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9UBU8

UPID:
MO4L1_HUMAN

ALTERNATIVE NAMES:
MORF-related gene 15 protein; Protein MSL3-1; Transcription factor-like protein MRG15

ALTERNATIVE UPACC:
Q9UBU8; B4DKN6; B7Z6R1; D3DW88; O95899; Q5QTS1; Q6NVX8; Q86YT7; Q9HBP6; Q9NSW5

BACKGROUND:
The protein Mortality factor 4-like protein 1, known under various names such as MORF-related gene 15 protein and Protein MSL3-1, is integral to the NuA4 histone acetyltransferase complex, influencing gene expression by modifying nucleosomal histones H4 and H2A. Its functions extend to growth induction, tumor suppression, replicative senescence, and DNA repair mechanisms. Mortality factor 4-like protein 1 is also essential for the effective localization of PALB2, BRCA2, and RAD51 to DNA-damage foci, highlighting its significance in maintaining genomic stability.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Mortality factor 4-like protein 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.